Transcriptional regulation of Rankl by Txnip-Ecd in aging and diabetic related osteoporosis.

ABSTRACT:

Introduction

Bone homeostasis between osteoclast bone resorption and osteoblastic bone formation is tightly regulated by a series of factors such as the receptor activator of nuclear factor-κB ligand (RANKL). Denosumab that neutralizes RANKL is effective and widely applied in the treatment of postmenopausal osteoporosis. However, factors that participated in the RANKL-related bone remodeling process in primary and secondary osteoporosis are less known.

Objectives

Revealing the novel transcriptional regulatory mechanism of RANKL is of great significance for the treatment of osteoporosis.

Methods

After differential expression genes (DEGs) intersection and screening, we generated Thioredoxin-interacting protein (Txnip) bone marrow-derived mesenchymal stromal cells (BMSCs

SUBMITTER: Cao X 

PROVIDER: S-EPMC12627875 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature